dupilumab


( Last Updated : April 6, 2021)
Generic Name:
dupilumab
Project Status:
Pending
Therapeutic Area:
atopic dermatitis, pediatrics
Manufacturer:
Sanofi Genzyme, a division of sanofi-aventis Canada Inc.
Call for patient/clinician input open:
Brand Name:
Dupixent
Project Line:
Reimbursement Review
Project Number:
SR0682-000
Call for patient/clinician input closed:

Details


Manufacturer Requested Reimbursement Criteria1:
Dupixent (dupilumab injection) is indicated for the treatment of patients aged 6 to 11 years with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. Dupixent can be used with or without topical corticosteroids.
Submission Type:
Initial
Fee Schedule:
Pending
Indications:
Dupixent (dupilumab injection) is indicated for the treatment of patients aged 6 to 11 years with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. DUPIXENT® can be used with or without topical corticosteroids.
  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.